Real-time · AI · Cross-signal

Vizgen just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on Vizgen, plus every funding round, exec hire, and M&A move that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your plan Request a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.

✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.

✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.

✕Clay enriches lists you built — No live signal of its own, no who or when.

✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.

Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Vizgen Secures $37M Series B Financing To Advance Spatial Genomics Through Commercialization Of Merscope™ Platform

PRIVATEApr 07, 2021•about 5 years ago

Amount Raised

$37 Million

Round Type

series b

Cambridge

Description

Vizgen, the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing. The financing was co-led by Novalis LifeSciences LLC, and current investor Northpond Ventures. Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund

Vizgen just raised. Here's exactly what to do next.

Vizgen Secures $37M Series B Financing To Advance Spatial Genomics Through Commercialization Of Merscope™ Platform

Description

Company Information

Funding Insights